Buy Himatsingka Seide, says Ambareesh Baliga of Karvy Stock Broking.

Baliga told CNBC-TV18, "We are buying Himatsingka Seide at this point of time. We are getting into stock like Vivimed Labs, which is not a midcap, it is a smallcap but at these levels we are finding these stocks attractively valued although that market risk is there that in case the market goes down to levels, which we have been talking about, these stocks could possibly cut another 10-15% from these levels but then buying for the next fifteen months, I don’t see a issue."

Disclosure: It is safe to assume that analyst and his clients may have an investment interest in the above stock/sector.